<?xml version="1.0" encoding="utf-8"?>
<rss 
  version="2.0">
  <channel xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/">
    <title>Acasti Pharma, Inc.</title>
    <link>https://www.globenewswire.com/rssfeed/organization/AjCHC-IWuo1zEUdQjgLBYw==</link>
    <description>Contains the last 20 releases</description>
    <copyright>Copyright 2023, Acasti Pharma, Inc.</copyright>
    <managingEditor>newsdesk@globenewswire.com (NewsDesk)</managingEditor>
    <lastBuildDate>Tue, 14 Feb 2023 12:00:00 GMT</lastBuildDate>
    <webMaster>webmaster@globenewswire.com (Webmaster)</webMaster>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2023/02/14/2607461/0/en/Acasti-Pharma-Reports-Third-Quarter-2023-Operational-Results.html</guid>
      <link>https://www.globenewswire.com/news-release/2023/02/14/2607461/0/en/Acasti-Pharma-Reports-Third-Quarter-2023-Operational-Results.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA00430K4028</category>
      <title>Acasti Pharma Reports Third Quarter 2023 Operational Results</title>
      <description><![CDATA[<p align="center"><strong><em>Company to Host Conference Call Today at 1:00pm ET</em></strong><br></p>]]></description>
      <pubDate>Tue, 14 Feb 2023 12:00 GMT</pubDate>
      <dc:identifier>2607461</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Acasti Pharma, Inc.</dc:contributor>
      <dc:modified>Tue, 14 Feb 2023 12:01 GMT</dc:modified>
      <dc:subject>Earnings Releases and Operating Results</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2023/01/25/2595249/0/en/Acasti-Receives-Extension-to-Regain-Compliance-with-NASDAQ-Minimum-Bid-Price-Rule.html</guid>
      <link>https://www.globenewswire.com/news-release/2023/01/25/2595249/0/en/Acasti-Receives-Extension-to-Regain-Compliance-with-NASDAQ-Minimum-Bid-Price-Rule.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA00430K4028</category>
      <title>Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule</title>
      <description><![CDATA[<p align="justify">LAVAL, Qu&#233;bec, Jan.  25, 2023  (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announces that it has received notification from the NASDAQ Listing Qualifications Department ("NASDAQ") that it is eligible for an additional 180 calendar days, or until July 24, 2023, to regain compliance with the minimum $1.00 per share requirement for continued listing.<br></p>]]></description>
      <pubDate>Wed, 25 Jan 2023 14:00 GMT</pubDate>
      <dc:identifier>2595249</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Acasti Pharma, Inc.</dc:contributor>
      <dc:modified>Wed, 25 Jan 2023 14:00 GMT</dc:modified>
      <dc:subject>Stock Market News</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2023/01/24/2594736/0/en/Acasti-Pharma-to-Present-at-Lytham-Partners-Investor-Select-Conference-on-January-31.html</guid>
      <link>https://www.globenewswire.com/news-release/2023/01/24/2594736/0/en/Acasti-Pharma-to-Present-at-Lytham-Partners-Investor-Select-Conference-on-January-31.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA00430K4028</category>
      <title>Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31</title>
      <description><![CDATA[<p align="justify">LAVAL, Qu&#233;bec, Jan.  24, 2023  (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced Jan D’Alvise, CEO, will present and host one-on-one meetings with investors at the Lytham Partners Investor Select Conference, taking place virtually on January 31, 2023.<br></p>]]></description>
      <pubDate>Tue, 24 Jan 2023 21:15 GMT</pubDate>
      <dc:identifier>2594736</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Acasti Pharma, Inc.</dc:contributor>
      <dc:modified>Tue, 24 Jan 2023 21:15 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:subject>Product / Services Announcement</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2023/01/13/2588611/0/en/Acasti-Pharma-to-Present-at-Sidoti-Virtual-Investor-Conference-on-January-18.html</guid>
      <link>https://www.globenewswire.com/news-release/2023/01/13/2588611/0/en/Acasti-Pharma-to-Present-at-Sidoti-Virtual-Investor-Conference-on-January-18.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA00430K4028</category>
      <title>Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18</title>
      <description><![CDATA[<p align="justify">LAVAL, Qu&#233;bec, Jan.  13, 2023  (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced Jan D’alvise, CEO, will present and host one-on-one meetings with investors at the Sidoti January Virtual Investor Conference, taking place on January 18-19, 2023.<br></p>]]></description>
      <pubDate>Fri, 13 Jan 2023 14:00 GMT</pubDate>
      <dc:identifier>2588611</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Acasti Pharma, Inc.</dc:contributor>
      <dc:modified>Fri, 13 Jan 2023 14:00 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2023/01/05/2583820/0/en/Acasti-to-Host-Conference-Call-on-Tuesday-January-10-2023-to-Discuss-Results-from-Recent-Phase-1-PK-Studies-for-GTX-101-and-GTX-102-That-Met-All-Outcome-Measures.html</guid>
      <link>https://www.globenewswire.com/news-release/2023/01/05/2583820/0/en/Acasti-to-Host-Conference-Call-on-Tuesday-January-10-2023-to-Discuss-Results-from-Recent-Phase-1-PK-Studies-for-GTX-101-and-GTX-102-That-Met-All-Outcome-Measures.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA00430K4028</category>
      <title>Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures</title>
      <description><![CDATA[<p align="justify">LAVAL, Qu&#233;bec, Jan.  05, 2023  (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that it will host a conference call on Tuesday, January 10, 2023 at 4:30 p.m. ET to review the recently reported preliminary topline results from two separate Phase 1 pharmacokinetic (PK) studies for GTX-101 and GTX-102. Both studies successfully met all target outcome measures.<br></p>]]></description>
      <pubDate>Thu, 05 Jan 2023 14:00 GMT</pubDate>
      <dc:identifier>2583820</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Acasti Pharma, Inc.</dc:contributor>
      <dc:modified>Thu, 05 Jan 2023 14:02 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:subject>Health</dc:subject>
      <dc:subject>Conference Calls/ Webcasts</dc:subject>
      <dc:subject>Clinical Study</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/12/28/2580187/0/en/Acasti-Announces-Preliminary-Topline-Results-Met-All-Outcome-Measures-in-the-Pharmacokinetic-Bridging-Study-for-GTX-102-the-Company-s-Drug-Candidate-for-the-Treatment-of-Ataxia-Tel.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/12/28/2580187/0/en/Acasti-Announces-Preliminary-Topline-Results-Met-All-Outcome-Measures-in-the-Pharmacokinetic-Bridging-Study-for-GTX-102-the-Company-s-Drug-Candidate-for-the-Treatment-of-Ataxia-Tel.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA00430K4028</category>
      <title>Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia</title>
      <description><![CDATA[<p align="justify">LAVAL, Qu&#233;bec, Dec.  28, 2022  (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announces that the preliminary topline results of the pharmacokinetic (PK) bridging study for GTX-102 met all outcome measures. The objectives of the study were to evaluate the bioavailability, pharmacokinetics, and safety of GTX-102, a novel, concentrated oral-mucosal metered spray of betamethasone in healthy volunteers. This new formulation is intended to improve the neurological symptoms of Ataxia Telangiectasia (A-T) in a pediatric population for which there are currently no FDA-approved therapies. GTX-102 can be sprayed conveniently over the tongue of A-T patients, who often have difficulties swallowing. This PK study was the next step in the proposed 505(b)(2) regulatory pathway for GTX-102.</p>]]></description>
      <pubDate>Wed, 28 Dec 2022 13:00 GMT</pubDate>
      <dc:identifier>2580187</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Acasti Pharma, Inc.</dc:contributor>
      <dc:modified>Wed, 28 Dec 2022 13:01 GMT</dc:modified>
      <dc:subject>Clinical Study</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/12/22/2578577/0/en/Acasti-Pharma-Announces-Preliminary-Topline-Results-Met-All-Primary-Outcome-Measures-in-the-Single-Dose-Pharmacokinetic-Study-for-GTX-101-the-Company-s-Drug-Candidate-for-the-Treat.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/12/22/2578577/0/en/Acasti-Pharma-Announces-Preliminary-Topline-Results-Met-All-Primary-Outcome-Measures-in-the-Single-Dose-Pharmacokinetic-Study-for-GTX-101-the-Company-s-Drug-Candidate-for-the-Treat.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA00430K4028</category>
      <title>Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)</title>
      <description><![CDATA[<p align="justify">LAVAL, Qu&#233;bec, Dec.  22, 2022  (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that preliminary topline results for its single-dose, pharmacokinetic (PK) bridging study to evaluate the relative bioavailability of GTX-101 compared to the reference listed drug in the U.S., bupivacaine subcutaneous injectable, met all primary outcome measures for the study. The final clinical study report is anticipated to be received by the Company in the first half of 2023. This PK study was the next step in the proposed 505(b)(2) regulatory pathway for GTX-101 and provides important information on the dose and dosing frequency in humans for future planned clinical studies.<br></p>]]></description>
      <pubDate>Thu, 22 Dec 2022 13:00 GMT</pubDate>
      <dc:identifier>2578577</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Acasti Pharma, Inc.</dc:contributor>
      <dc:modified>Thu, 22 Dec 2022 13:01 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
      <dc:subject>Research Analysis and Reports</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/11/14/2554817/0/en/Acasti-Pharma-Reports-Second-Quarter-2023-Operational-Results.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/11/14/2554817/0/en/Acasti-Pharma-Reports-Second-Quarter-2023-Operational-Results.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA00430K4028</category>
      <title>Acasti Pharma Reports Second Quarter 2023 Operational Results</title>
      <description><![CDATA[<p align="center"><strong><em>Company to Host Conference Call Today at 1:00pm ET</em></strong><br></p>]]></description>
      <pubDate>Mon, 14 Nov 2022 12:00 GMT</pubDate>
      <dc:identifier>2554817</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Acasti Pharma, Inc.</dc:contributor>
      <dc:modified>Mon, 14 Nov 2022 12:01 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:subject>Earnings Releases and Operating Results</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/11/09/2552493/0/en/Acasti-Pharma-to-Present-at-Q4-Investor-Summit.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/11/09/2552493/0/en/Acasti-Pharma-to-Present-at-Q4-Investor-Summit.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA00430K4028</category>
      <title>Acasti Pharma to Present at Q4 Investor Summit</title>
      <description><![CDATA[<p align="justify">LAVAL, Qu&#233;bec, Nov.  09, 2022  (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that Jan D’Alvise, President and CEO of Acasti Pharma will be presenting virtually at the Q4 Investor Summit. The Company will be conducting a webcasted presentation and participating in one-on-one meetings with investors.<br></p>]]></description>
      <pubDate>Wed, 09 Nov 2022 21:15 GMT</pubDate>
      <dc:identifier>2552493</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Acasti Pharma, Inc.</dc:contributor>
      <dc:modified>Wed, 09 Nov 2022 21:15 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:subject>Trade Show</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/11/07/2550272/0/en/Acasti-Pharma-to-Report-Second-Quarter-2023-Financial-Results-on-Monday-November-14-2022.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/11/07/2550272/0/en/Acasti-Pharma-to-Report-Second-Quarter-2023-Financial-Results-on-Monday-November-14-2022.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA00430K4028</category>
      <title>Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022</title>
      <description><![CDATA[Call to be held on Monday, November 14th at 1:00 PM Eastern Time <pre>Call to be held on Monday, November 14th at 1:00 PM Eastern Time</pre>]]></description>
      <pubDate>Mon, 07 Nov 2022 21:15 GMT</pubDate>
      <dc:identifier>2550272</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Acasti Pharma, Inc.</dc:contributor>
      <dc:modified>Mon, 07 Nov 2022 21:15 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:subject>Conference Calls/ Webcasts</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/09/30/2526030/0/en/Acasti-Announces-Court-Dismissal-of-Stockholder-Litigation.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/09/30/2526030/0/en/Acasti-Announces-Court-Dismissal-of-Stockholder-Litigation.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA00430K4028</category>
      <title>Acasti Announces Court Dismissal of Stockholder Litigation </title>
      <description><![CDATA[<p align="justify">LAVAL, Qu&#233;bec, Sept.  30, 2022  (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announced today that a U.S. court has dismissed the remaining stockholder litigation filed in connection with the Company’s acquisition of Grace Therapeutics, Inc. (“<strong>Grace</strong>”) via merger in August 2021 (the “<strong>Merger</strong>”). As previously disclosed, four stockholder lawsuits were filed against Acasti and certain of its directors and officers in connection with the Merger, claiming that the Company’s public disclosures relating to the Merger misstated or omitted material information and violated Section 14(a) of the U.S. Securities Exchange Act of 1934. Two of the four cases were voluntarily dismissed. The remaining two cases were consolidated before Judge Katherine Polk Failla in the United States District Court for the Southern District of New York. Acasti and the individual defendants filed a motion to dismiss on February 25, 2022. In a 45-page opinion released earlier today, Judge Failla granted the motion to dismiss in its entirety, finding that the consolidated complaint failed to allege any facts showing that Acasti made a materially misleading statement or material omission in its Merger-related disclosures. Accordingly, subject to any appeal that may be taken in response to today’s ruling, all four stockholder suits filed in connection with the Merger have now been dismissed.<br></p>]]></description>
      <pubDate>Fri, 30 Sep 2022 13:00 GMT</pubDate>
      <dc:identifier>2526030</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Acasti Pharma, Inc.</dc:contributor>
      <dc:modified>Fri, 30 Sep 2022 13:00 GMT</dc:modified>
      <dc:subject>Law &amp; Legal Issues</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/09/29/2525246/0/en/Acasti-Announces-Voting-Results-from-2022-Annual-and-Special-Meeting-of-Shareholders.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/09/29/2525246/0/en/Acasti-Announces-Voting-Results-from-2022-Annual-and-Special-Meeting-of-Shareholders.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA00430K4028</category>
      <title>Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders</title>
      <description><![CDATA[<p align="justify">LAVAL, Qu&#233;bec, Sept.  29, 2022  (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“<strong>Acasti</strong>” or the “<strong>Company</strong>”) (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announced today the voting results from its Annual General and Special Meeting of Shareholders (the “<strong>Meeting</strong>”) which was held virtually on Wednesday September 28, 2022.<br></p>]]></description>
      <pubDate>Thu, 29 Sep 2022 13:00 GMT</pubDate>
      <dc:identifier>2525246</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Acasti Pharma, Inc.</dc:contributor>
      <dc:modified>Thu, 29 Sep 2022 13:00 GMT</dc:modified>
      <dc:subject>Annual Meetings &amp; Shareholder Rights</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/09/14/2516401/0/en/Acasti-Pharma-to-Participate-in-the-Lytham-Partners-Fall-2022-Investor-Conference.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/09/14/2516401/0/en/Acasti-Pharma-to-Participate-in-the-Lytham-Partners-Fall-2022-Investor-Conference.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA00430K4028</category>
      <title>Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference</title>
      <description><![CDATA[<p align="justify">LAVAL, Qu&#233;bec, Sept.  14, 2022  (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, announced today that it will be participating in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022.<br></p>]]></description>
      <pubDate>Wed, 14 Sep 2022 20:15 GMT</pubDate>
      <dc:identifier>2516401</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Acasti Pharma, Inc.</dc:contributor>
      <dc:modified>Wed, 14 Sep 2022 20:15 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/09/13/2514909/0/en/Acasti-Pharma-Announces-Initiation-of-Pharmacokinetic-Study-for-GTX-102-the-Company-s-Drug-Candidate-for-the-Treatment-of-Ataxia-Telangiectasia.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/09/13/2514909/0/en/Acasti-Pharma-Announces-Initiation-of-Pharmacokinetic-Study-for-GTX-102-the-Company-s-Drug-Candidate-for-the-Treatment-of-Ataxia-Telangiectasia.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA00430K4028</category>
      <title>Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia</title>
      <description><![CDATA[<p align="justify">LAVAL, Qu&#233;bec, Sept.  13, 2022  (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the comparative bioavailability, pharmacokinetics, and safety of its oral betamethasone spray, GTX-102, compared to an intramuscular injection of betamethasone and to an oral solution of betamethasone, in 48 healthy subjects. The First Subject, First Dose was administered on September 13<sup>th</sup>. This PK study is the next step in the proposed 505(b)(2) regulatory pathway for GTX-102 and is expected to be completed with top line results reported before year end.<br></p>]]></description>
      <pubDate>Tue, 13 Sep 2022 12:00 GMT</pubDate>
      <dc:identifier>2514909</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Acasti Pharma, Inc.</dc:contributor>
      <dc:modified>Tue, 13 Sep 2022 12:01 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
      <dc:subject>Product / Services Announcement</dc:subject>
      <dc:subject>Clinical Study</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/09/12/2514143/0/en/Acasti-Pharma-to-Participate-at-the-H-C-Wainwright-24th-Annual-Global-Investment-Conference.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/09/12/2514143/0/en/Acasti-Pharma-to-Participate-at-the-H-C-Wainwright-24th-Annual-Global-Investment-Conference.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA00430K4028</category>
      <title>Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference</title>
      <description><![CDATA[<p align="justify">LAVAL, Qu&#233;bec, Sept.  12, 2022  (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today announced that management will virtually participate at the H.C. Wainwright 24th Annual Global Investment Conference September 12-16, 2022.<br></p>]]></description>
      <pubDate>Mon, 12 Sep 2022 13:00 GMT</pubDate>
      <dc:identifier>2514143</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Acasti Pharma, Inc.</dc:contributor>
      <dc:modified>Mon, 12 Sep 2022 13:01 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:subject>Conference Calls/ Webcasts</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/08/11/2496592/0/en/Acasti-Pharma-Reports-First-Quarter-2023-Operational-Results.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/08/11/2496592/0/en/Acasti-Pharma-Reports-First-Quarter-2023-Operational-Results.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA00430K4028</category>
      <title>Acasti Pharma Reports First Quarter 2023 Operational Results</title>
      <description><![CDATA[Company to Host Conference Call Today at 1:00pm ET <pre>Company to Host Conference Call Today at 1:00pm ET</pre>]]></description>
      <pubDate>Thu, 11 Aug 2022 11:00 GMT</pubDate>
      <dc:identifier>2496592</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Acasti Pharma, Inc.</dc:contributor>
      <dc:modified>Thu, 11 Aug 2022 11:01 GMT</dc:modified>
      <dc:subject>Earnings Releases and Operating Results</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/08/02/2490881/0/en/Acasti-Pharma-to-Report-First-Quarter-2023-Financial-Results-on-Thursday-August-11-2022.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/08/02/2490881/0/en/Acasti-Pharma-to-Report-First-Quarter-2023-Financial-Results-on-Thursday-August-11-2022.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA00430K4028</category>
      <title>Acasti Pharma to Report First Quarter 2023 Financial Results on Thursday, August 11, 2022</title>
      <description><![CDATA[<p align="center"><strong>Call to be held on Thursday, August 11th at 1:00 PM Eastern Time</strong><br></p>]]></description>
      <pubDate>Tue, 02 Aug 2022 20:15 GMT</pubDate>
      <dc:identifier>2490881</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Acasti Pharma, Inc.</dc:contributor>
      <dc:modified>Tue, 02 Aug 2022 20:15 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:subject>Conference Calls/ Webcasts</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/07/27/2486813/0/en/Acasti-Pharma-Announces-Initiation-of-Pharmacokinetic-Study-for-GTX-101-the-Company-s-Drug-Candidate-for-the-Treatment-of-Postherpetic-Neuralgia.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/07/27/2486813/0/en/Acasti-Pharma-Announces-Initiation-of-Pharmacokinetic-Study-for-GTX-101-the-Company-s-Drug-Candidate-for-the-Treatment-of-Postherpetic-Neuralgia.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA00430K4028</category>
      <title>Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia</title>
      <description><![CDATA[<p align="justify">LAVAL, Quebec, July  27, 2022  (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the relative bioavailability of GTX-101 compared to the reference listed drug bupivacaine in 48 healthy subjects. Feedback from FDA was obtained on the study protocol, and the non-objection letter was received on July 12<sup>th</sup> from Health Canada. The First-Subject, First-Dose was administered on July 26<sup>th</sup>. The PK study is the next step in the proposed 505(b)(2) regulatory pathway for GTX-101. This study is expected to be completed by the end of calendar 2022 as planned and will provide important information on the dose and dosing frequency in humans.<br></p>]]></description>
      <pubDate>Wed, 27 Jul 2022 12:00 GMT</pubDate>
      <dc:identifier>2486813</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Acasti Pharma, Inc.</dc:contributor>
      <dc:modified>Wed, 27 Jul 2022 12:01 GMT</dc:modified>
      <dc:subject>Clinical Study</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/06/22/2467552/0/en/Acasti-Pharma-Announces-Annual-Grants-of-Performance-Stock-Options.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/06/22/2467552/0/en/Acasti-Pharma-Announces-Annual-Grants-of-Performance-Stock-Options.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA00430K4028</category>
      <title>Acasti Pharma Announces Annual Grants of Performance Stock Options</title>
      <description><![CDATA[<p align="justify">LAVAL, Qu&#233;bec, June  22, 2022  (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today announced the annual grant of performance stock options to its employees and executives.<br></p>]]></description>
      <pubDate>Wed, 22 Jun 2022 22:10 GMT</pubDate>
      <dc:identifier>2467552</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Acasti Pharma, Inc.</dc:contributor>
      <dc:modified>Wed, 22 Jun 2022 22:10 GMT</dc:modified>
      <dc:subject>Stock Market News</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2022/06/21/2466075/0/en/Acasti-Pharma-Reports-Fiscal-Year-2022-Operational-Results.html</guid>
      <link>https://www.globenewswire.com/news-release/2022/06/21/2466075/0/en/Acasti-Pharma-Reports-Fiscal-Year-2022-Operational-Results.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">TSX-V:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:ACST</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">CA00430K4028</category>
      <title>Acasti Pharma Reports Fiscal Year 2022 Operational Results</title>
      <description><![CDATA[<p align="center"><strong><em>Company to Host Conference Call Today at 1:00pm ET</em></strong><br></p>]]></description>
      <pubDate>Tue, 21 Jun 2022 12:00 GMT</pubDate>
      <dc:identifier>2466075</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>Acasti Pharma, Inc.</dc:contributor>
      <dc:modified>Tue, 21 Jun 2022 12:00 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:subject>Earnings Releases and Operating Results</dc:subject>
      <dc:subject>Conference Calls/ Webcasts</dc:subject>
    </item>
  </channel>
</rss>